{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-003740","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2026-06-09T23:04:13+00:00","discovered_at":"2026-06-10T10:05:00.211265+00:00","generated_at":"2026-06-10T10:09:02.218740+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VolitionRx prices $4.6M public offering of common stock and warrants","bullets":["Offered 2,960,000 shares at $1.55 each plus half-warrant; gross proceeds ~$4.6M.","Net proceeds ~$4.1M after fees; additional $2.3M possible if warrants fully exercised.","Use of proceeds: R&D, clinical studies, commercialization, working capital, repaying secured convertible notes.","Maxim Group LLC acted as sole placement agent; offering closed June 9, 2026.","Warrants exercisable at $1.55 per share immediately, expire in 5 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003740","json":"https://secwatch.observer/filing/0001477932-26-003740.json","markdown":"https://secwatch.observer/filing/0001477932-26-003740.md","text":"https://secwatch.observer/filing/0001477932-26-003740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003740/0001477932-26-003740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003740/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:09:02.218740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e4c220f2b81f2941fee98254924017dfcb61830","claim":"VOLITIONRX LTD entered into Purchase Agreement with the purchasers listed on the signature pages thereto valued at $1.55 per Share and accompanying Warrant (effective 2026-06-07).","evidence_excerpt":"On June 7, 2026, VolitionRx Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers listed on the signature pages thereto (the “Purchasers”), in connection with the Company’s offer of an aggregate of 2,960,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase 1,480,000 shares of Common Stock (the “Warrants” and, together with the Shares, the “Securities”) to the Purchasers and other investors who purchased Securities pursuant to the prospectus registering such Securities (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003740/0001477932-26-003740-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers listed on the signature pages thereto"},{"label":"Value","value":"$1.55 per Share and accompanying Warrant"},{"label":"Effective","value":"2026-06-07"}],"fact_type":"material_agreement"},{"claim_id":"d6b8f7fdfbcee0cc2e08d743f769cc87df25481c","claim":"VOLITIONRX LTD entered into Placement Agency Agreement with Maxim Group LLC (effective 2026-06-07).","evidence_excerpt":"The Offering was conducted as a confidentially marketed public offering on a reasonable best efforts basis by Maxim acting as sole placement agent for the Company pursuant to a Placement Agency Agreement, dated June 7, 2026 (the “Placement Agency Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226003740/0001477932-26-003740-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2026-06-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}